ReviewImmunotherapy2017
Leveraging natural killer cells for cancer immunotherapy.
Review in Immunotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07225439 (Phase I Clinical Trial of Rituximab), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Uncovering global research frontiers in deubiquitinating enzymes and immunotherapy: A bibliometric study.Human vaccines & immunotherapeutics · 2025Article
- Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.Experimental hematology & oncology · 2025Review
- Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.Frontiers in immunology · 2024Review
- Article
- Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy.Frontiers in immunology · 2022Review
- Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.Stem cell research & therapy · 2021Review
- Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner.Oncoimmunology · 2021Article
- A high-throughput assay for screening natural products that boost NK cell-mediated killing of cancer cells.Pharmaceutical biology · 2020Article
- NK Cell-Based Immune Checkpoint Inhibition.Frontiers in immunology · 2020Review
- The Roles of circRNAs in Liver Cancer Immunity.Frontiers in oncology · 2020Review
- Pembrolizumab for anaplastic thyroid cancer: a case study.Cancer immunology, immunotherapy : CII · 2019Article
- Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.Journal of clinical medicine · 2019Review
- Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.Frontiers in oncology · 2019Review
- Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy.Ochsner journal · 2019Article
- NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.The Journal of clinical investigation · 2018Article
- Immunoreceptor tyrosine-based inhibitory motif-dependent functions of an MHC class I-specific NK cell receptor.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.Seminars in immunology · 2017Review
- Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells.OncoimmunologyArticle
- NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Natural killer (NK) cells are potent antitumor effector cells of the innate immune system. Based on their ability to eradicate tumors in vitro and in animal models, significant enthusiasm surrounds the prospect of leveraging human NK cells as vehicles for cancer immunotherapy. While interest in manipulating the effector functions of NK cells has existed for over 30 years, there is renewed optimism for this approach today. Although T cells receive much of the clinical and preclinical attention when it comes to cancer immunotherapy, new strategies are utilizing adoptive NK-cell immunotherapy and monoclonal antibodies and engineered molecules which have been developed to specifically activate NK cells against tumors. Despite the numerous challenges associated with the preclinical and clinical development of NK cell-based therapies for cancer, NK cells possess many unique immunological properties and hold the potential to provide an effective means for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.